Island Pharmaceuticals
ASX:ILACamberwell, Australia· Est.
Australian biotech repurposing antivirals for dengue and other vector‑borne diseases, with a Phase 2a/b trial of ISLA‑101.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian biotech repurposing antivirals for dengue and other vector‑borne diseases, with a Phase 2a/b trial of ISLA‑101.
Infectious DiseasesVirologyAntiviral
Technology Platform
Drug repurposing of orally administered antivirals with known safety profiles to accelerate development for unmet infectious disease indications.
Opportunities
Successful Phase 2 data for ISLA‑101 could enable fast‑track regulatory pathways and partnership deals; acquisition of galidesivir would broaden the antiviral portfolio and address emerging RNA virus threats.
Risk Factors
Clinical trial failure or safety concerns for ISLA‑101; challenges in completing the galidesivir acquisition; limited cash runway as a pre‑revenue company.
Competitive Landscape
Competes with other antiviral developers and repurposing firms; differentiation lies in its oral formulation and rapid development timeline leveraging known safety data.